Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

LoneStar Heart Raises $20 Million in Round Led by Hong Kong PE Firm

publication date: Oct 9, 2012
LoneStar Heart of California has raised up to $20 million in a milestone-based equity financing, which the company will use to support clinical development its lead product, Algisyl-LVR. The product, considered a medical device, is a biopolymer that is implanted into the left ventricle wall of the heart to treat advanced heart failure. The financing was led by Themes Investment Partners, a Hong Kong PE fund focused on China markets. The capital will be used to conduct clinical trials in Europe (already underway), followed by China. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital